143 related articles for article (PubMed ID: 33964112)
1. Investigation of water-insoluble hydrophobic polyethylenimines as RNAi vehicles in chronic myeloid leukemia therapy.
Ansari AS; K C R; Jiang X; Uludaǧ H
J Biomed Mater Res A; 2021 Nov; 109(11):2306-2321. PubMed ID: 33964112
[TBL] [Abstract][Full Text] [Related]
2. Investigating siRNA delivery to chronic myeloid leukemia K562 cells with lipophilic polymers for therapeutic BCR-ABL down-regulation.
Valencia-Serna J; Gul-Uludağ H; Mahdipoor P; Jiang X; Uludağ H
J Control Release; 2013 Dec; 172(2):495-503. PubMed ID: 23726887
[TBL] [Abstract][Full Text] [Related]
3. Cholesterol grafted cationic lipopolymers: Potential siRNA carriers for selective chronic myeloid leukemia therapy.
Remant KC; Thapa B; Valencia-Serna J; Domun SS; Dimitroff C; Jiang X; Uludağ H
J Biomed Mater Res A; 2020 Mar; 108(3):565-580. PubMed ID: 31714657
[TBL] [Abstract][Full Text] [Related]
4. siRNA-mediated BCR-ABL silencing in primary chronic myeloid leukemia cells using lipopolymers.
Valencia-Serna J; Kucharski C; Chen M; Kc R; Jiang X; Brandwein J; Uludağ H
J Control Release; 2019 Sep; 310():141-154. PubMed ID: 31430499
[TBL] [Abstract][Full Text] [Related]
5.
Kc R; Thapa B; Ubeda A; Jiang X; Uludağ H
Stem Cells Dev; 2019 Jun; 28(11):734-744. PubMed ID: 30585758
[TBL] [Abstract][Full Text] [Related]
6. siRNA/lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo.
Valencia-Serna J; Aliabadi HM; Manfrin A; Mohseni M; Jiang X; Uludag H
Eur J Pharm Biopharm; 2018 Sep; 130():66-70. PubMed ID: 29913272
[TBL] [Abstract][Full Text] [Related]
7. Small hydrophobe substitution on polyethylenimine for plasmid DNA delivery: Optimal substitution is critical for effective delivery.
Thapa B; Plianwong S; Remant Bahadur KC; Rutherford B; Uludağ H
Acta Biomater; 2016 Mar; 33():213-24. PubMed ID: 26802444
[TBL] [Abstract][Full Text] [Related]
8. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells].
Wang S; Chai YB; Liu F; Zhang XY; Jia W; Xie X; Yu WQ; Shang ZC; Jin BQ; Sun BZ
Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(3):198-202. PubMed ID: 15854468
[TBL] [Abstract][Full Text] [Related]
9. Bcr-abl silencing by specific small-interference RNA expression vector as a potential treatment for chronic myeloid leukemia.
Zaree Mahmodabady A; Javadi HR; Kamali M; Najafi A; Hojati Z
Iran Biomed J; 2010; 14(1-2):1-8. PubMed ID: 20683492
[TBL] [Abstract][Full Text] [Related]
10. Delivery of therapeutic shRNA and siRNA by Tat fusion peptide targeting BCR-ABL fusion gene in Chronic Myeloid Leukemia cells.
Arthanari Y; Pluen A; Rajendran R; Aojula H; Demonacos C
J Control Release; 2010 Aug; 145(3):272-80. PubMed ID: 20403398
[TBL] [Abstract][Full Text] [Related]
11. Biodegradable charged polyester-based vectors (BCPVs) as an efficient non-viral transfection nanoagent for gene knockdown of the BCR-ABL hybrid oncogene in a human chronic myeloid leukemia cell line.
Yang C; Panwar N; Wang Y; Zhang B; Liu M; Toh H; Yoon HS; Tjin SC; Chong PH; Law WC; Chen CK; Yong KT
Nanoscale; 2016 Apr; 8(17):9405-16. PubMed ID: 27092903
[TBL] [Abstract][Full Text] [Related]
12. Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo.
Jyotsana N; Sharma A; Chaturvedi A; Budida R; Scherr M; Kuchenbauer F; Lindner R; Noyan F; Sühs KW; Stangel M; Grote-Koska D; Brand K; Vornlocher HP; Eder M; Thol F; Ganser A; Humphries RK; Ramsay E; Cullis P; Heuser M
Ann Hematol; 2019 Aug; 98(8):1905-1918. PubMed ID: 31104089
[TBL] [Abstract][Full Text] [Related]
13. RNA interference targeting of Bcr-Abl increases chronic myeloid leukemia cell killing by 17-allylamino-17-demethoxygeldanamycin.
Withey JM; Harvey AJ; Crompton MR
Leuk Res; 2006 May; 30(5):553-60. PubMed ID: 16260034
[TBL] [Abstract][Full Text] [Related]
14. Additive antileukemia effects by GFI1B- and BCR-ABL-specific siRNA in advanced phase chronic myeloid leukemic cells.
Koldehoff M; Zakrzewski JL; Beelen DW; Elmaagacli AH
Cancer Gene Ther; 2013 Jul; 20(7):421-7. PubMed ID: 23788109
[TBL] [Abstract][Full Text] [Related]
15. Before and after endosomal escape: roles of stimuli-converting siRNA/polymer interactions in determining gene silencing efficiency.
Kwon YJ
Acc Chem Res; 2012 Jul; 45(7):1077-88. PubMed ID: 22103667
[TBL] [Abstract][Full Text] [Related]
16. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
[TBL] [Abstract][Full Text] [Related]
17. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
Liao HF; Su YC; Zheng ZY; Jhih Cai C; Hou MH; Chao KS; Chen YJ
Biomed Pharmacother; 2012 Jul; 66(5):378-83. PubMed ID: 22397755
[TBL] [Abstract][Full Text] [Related]
18. Polyethylenimine PEI F25-LMW allows the long-term storage of frozen complexes as fully active reagents in siRNA-mediated gene targeting and DNA delivery.
Höbel S; Prinz R; Malek A; Urban-Klein B; Sitterberg J; Bakowsky U; Czubayko F; Aigner A
Eur J Pharm Biopharm; 2008 Sep; 70(1):29-41. PubMed ID: 18499413
[TBL] [Abstract][Full Text] [Related]
19. BCR/ABL mRNA targeting small interfering RNA effects on proliferation and apoptosis in chronic myeloid leukemia.
Zhu XS; Lin ZY; Du J; Cao GX; Liu G
Asian Pac J Cancer Prev; 2014; 15(12):4773-80. PubMed ID: 24998540
[TBL] [Abstract][Full Text] [Related]
20. siRNA-cell-penetrating peptides complexes as a combinatorial therapy against chronic myeloid leukemia using BV173 cell line as model.
Freire JM; Rego de Figueiredo I; Valle J; Veiga AS; Andreu D; Enguita FJ; Castanho MA
J Control Release; 2017 Jan; 245():127-136. PubMed ID: 27890856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]